MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy

作     者：Torben Frøstrup Hansen Anting Liu Carlsen Julia Tanas Tanassi Ole Larsen Flemming Brandt Sørensen Lars Henrik Jensen Anders Jakobsen 

作者机构：Danish Colorectal Cancer Center SouthVejle HospitalInstitute of Regional Health ResearchUniversity of Southern DenmarkVejle 7100Denmark Department of Autoimmunology and BiomarkersStatens Serum InstitutCopenhagen 2300Denmark Department of Congenital DisordersStatens Serum InstitutCopenhagen 2300Denmark Department of OncologyHerlev HospitalHerlev 2730Denmark University Institute of PathologyAarhus University Hospitaland department of Clinical MedicineUniversity of AarhusAarhus 8200Denmark 

出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)

年 卷 期：2019年第2卷第3期

页      面：885-896页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was supported by the Cancer Foundation(no reference),the Danish Council for Independent Research(No.10-093589) Direktør Jacob Madsen&Hustru Olga Madsen’s Foundation(No.5297) the Regional Strategic Council for Research in the Region of Southern Denmark(No.14/32395) 

主　　题：Chemotherapy colon cancer epidermal growth factor-like domain 7 microRNA-126 

摘      要：Aim:Neoadjuvant chemotherapy may represent a shift in the treatment of locally advanced colon *** angiogenic couple has-microRNA-126(miRNA-126)and epidermal growth factor-like domain 7(EGFL7)are transcribed from the same gene and regulates all aspects of angiogenesis and may influence the ability of tumor cells to *** aim was to analyze the relationship between miRNA-126 and EGFL7 and disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant ***:This study included 71 patients from a phase II study all planned for three cycles of capecitabine and oxaliplatin before *** was sampled at baseline and right before and after the *** miRNA-126 was analysed by RT-qPCR and a quantitative immunoassay was used for the analyses of ***:The rates of 5-year disease-free survival(DFS)and overall survival(OS)were 80%and 85%,*** level of circulating miRNA-126 before the operation predicts recurrence,P=*** patients with values below and above the median the recurrence rate was 31%and 4%,*** results applied to EGFL7.A combined estimate identified a subgroup of patients(25 of 71)with no recurrence and a 5-year DFS and OS rate of 100%,***:MicroRNA-126 and EGFL7 are predictors for disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy and may assist in selection of adjuvant chemotherapy.